Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 1998

View Archived Issues

Connetics to develop clobetasol mousse for dermatoses

Novel AIDS Rx technology available for licensing from NIH

IP-10 available for licensing from NIH

Cancer gene therapy technology available for licensing from NIH

Novel polyspecific antibody-agent conjugates from Immunomedics

Oral heparin preparation completes additional phase I trials

Anti-IL-4 antibodies from Schering-Plough

Onyx and Warner-Lambert renew cell cycle regulation agreement

Gliadel Wafer enters additional phase III study

SU-101 advances to phase III for relapsed glioblastoma

PROACT trial results published

Compounds for cardiovascular diseases described by BMS

BASF reports new endothelin antagonists

Inhibitors of iNOS developed at Astra

Ebselen shows promise in the treatment of acute ischemic stroke

DuPont Merck develops new factor Xa inhibitors as anticoagulants

Takeda discloses compounds for cachexia

Daclizumab efficacy demonstrated in transplant recipients

Lilly claims another series of heterocyclic muscarinic receptor modulators

U. of Mass. scientists design anti-EBV antisense oligonucleotides

Inhibition of monocyte-endothelial cell adhesion in atherogenesis by anti-CD43 MAb

Joint effort on cancer vaccine development

Sugen and Asta Medica make progress in Pan-HER collaboration

Unimed submits NDA for AIDS-related illness

Tyrosine kinase inhibitor shows potential for leukemias

Further mechanism of action studies described for AMD-3100

Anti-HIV therapy with adefovir may also prevent the development of Kaposi's sarcoma

SuperGen cleared to manufacture commercial supplies of Nipent

Paxene tentatively approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...